SHS Capital has the portfolio. The timing. The leadership appetite. What's missing is someone who owns the AI topic end-to-end -from identifying where value sits, to making it happen, to proving the EUR impact. This proposal outlines how we get there, starting with MTR.
Two AI solutions designed specifically for MTR Medizintechnik's field force. Built to show what's possible - not in theory, but as a working prototype you can click through today.
Click through the live prototype. Bookmark and share with the team.
After every patient visit, the field rep types a few bullet points -or dictates voice notes -and the AI generates a complete, structured CRM report. Instantly.
What gets generated: Structured summary, products discussed, follow-up actions (e.g. "process prescription, submit Kostenübernahme to insurer, schedule patient fitting"), and a sentiment analysis per doctor.
Time saved: ~30 minutes per visit report. With 120–150 reps making multiple visits daily, the aggregate savings are significant -and every report is complete, consistent, and CRM-ready from day one.
Before the next appointment, the rep requests a one-click briefing. The AI pulls together everything relevant -history, products, opportunities, and a conversation guide.
What gets generated: Relationship status, past orders and fittings, relevant product recommendations, identified opportunities (e.g. "competitor dissatisfaction -emphasise faster response times"), and a tailored conversation guide per doctor.
This is where revenue is created. The Visit Report saves time. The Visit Prep creates value. Better-prepared reps close more fittings, identify cross-sell opportunities, and build stronger physician relationships -systematically, not by gut feel.
A management-level view for the SHS Value Creation Team. One dashboard showing AI status, use cases, impact metrics, and next steps across all portfolio companies.
Each portfolio company gets a card showing: the AI use case in progress, implementation status, next steps, time savings and productivity gains, and sprint-to-pilot timeline. Updated automatically as implementations progress.
Note on CRM integration: Both modules connect to whatever CRM system MTR uses -the doctor dropdowns pull from CRM data, and saved reports flow back in. We need to identify MTR's CRM and confirm API access as a first step. Build or buy decision for the final tool follows from there.
We don't roll this out to 150 reps on day one. We start with a regional pilot -10 to 20 reps in one territory. Measure adoption, gather feedback, quantify the time savings. Then expand based on data, not assumptions.
One track for SHS Capital at fund level. One for the first portfolio company. Each with its own scope and deliverables.
Your AI person at SHS -for the fund and for the portfolio.
"Irgendwo sind bei uns die Grenzen, und man kann sich nicht in jedes Thema reinlesen und dann sicher sagen, das macht Sinn oder das macht nicht Sinn. Bei uns ist das maximal Bauchgefühl -und das sollte es nicht sein."
— Guillaume Balz, SHS Capital, 01 April 2026
90 days to first proven AI savings in the portfolio.
As soon as the first learnings are in, we scale what works.
SHS Capital operates in a regulated environment -subject to BaFin oversight, DORA requirements, and EU-wide data protection and AI regulation. These aren't reasons to avoid AI. They're reasons to get the approach right from the start.
Every AI tool decision in a BaFin-regulated environment has a compliance dimension. I make sure the right questions are on the table before a tool is deployed, not after -so you never get surprised by a regulatory issue you could have seen coming.
For every portfolio company implementation: EU/Germany hosting by default. No patient data in AI systems. DSGVO-compliant data flows as a non-negotiable baseline. If formal risk classification under the EU AI Act is needed, I bring in the right people.
If deep regulatory, legal, or architectural expertise is needed, I identify the right partners and coordinate their work so it feeds directly into the AI strategy. No duplicate workstreams, no gaps.
AI pilot, fund-level advisory, and portfolio workshop - bundled into a single monthly engagement. Invoicing can be split across entities if needed.
Strategy, development, implementation, vendor evaluation, regulatory awareness, and portfolio rollout - one person, one engagement, no coordination overhead.
| What's included | Duration | Investment |
|---|---|---|
| AI Pilot & Advisory MTR Field Force AI (2 solutions, CRM integration, field testing, EBITDA proof) + Fund-level advisory (vendor evaluation, regulatory awareness, monthly reporting) + Portfolio AI Kick-off Workshop |
6 months | EUR 15.500/mo |
| Portfolio Roll-Out (per additional company) Individually scoped. Faster start because playbook exists. Cross-portfolio leverage, EBITDA tracking. |
3-6 months per company | EUR 10.000 - 15.000/mo |
Invoicing can be split across SHS and MTR entities. 3-month minimum, then monthly rolling with 30 days written notice.
EUR 93.000 for six months is less than a single mid-level hire - but delivers AI strategy, two working AI solutions, a portfolio workshop, vendor evaluation, regulatory guidance, and a rollout playbook. One wrong software decision or six months of delay typically costs more.
All fees quoted are net amounts. Statutory VAT (currently 19%) will be added. Travel expenses (e.g. for on-site workshops, portfolio company visits) are billed at cost. All savings estimates are illustrative and based on the assumptions stated -they do not constitute performance guarantees. Engagement governed by separate services agreement.
ROI on 6-month engagement (EUR 93K): ~4.3x. Revenue uplift from better-prepared visits not included in base case.
Why this investment level: A single AI vendor decision - correctly evaluated - can save or cost SHS six figures. The retainer gives you a trusted partner who understands both your portfolio and the technology - always available, always current. Dedicated project work - implementation, training, compliance deep-dives - is scoped and agreed separately, so you only pay for what you actually need.
No tool is ever recommended unless it solves a specific, identified problem at a specific company. Build or buy -decided together, case by case.
Every engagement runs until the change is implemented and measurable. Not until the slides are delivered.
3-month minimum, then monthly rolling with 30 days written notice. Each phase has a concrete deliverable and a decision gate.
One senior Fractional CAIO. Directly accountable. No juniors. No overhead. No 40-page decks nobody reads.
Strategy and implementation from one person. I decide what gets built, build the first version myself, and steer external partners for complex integrations. No handover gap.
No team rotation, no junior analysts. You work with the same person from discovery through handover. Every recommendation has my name on it.
Every recommendation accounts for DSGVO, BaFin, DORA, and EU AI Act. Not as an afterthought -as a starting point.
Healthcare. PE-backed. Operational focus. Measurable EUR impact.
Specialty Pharmaceuticals · Enterprise Value EUR 1.8bn
Multi-workshop AI transformation programme with the senior leadership team. Discovery interviews across all seven functions. AI Opportunity Matrix with 20+ use cases. Corporate AI vision signed off. Governance framework with six AI Golden Rules.
"By the end of the third session, there was no debate left. Everyone saw where time was being lost. Everyone agreed what to do next. That clarity is rare."
Owner-managed · Senior Leadership Team
"Everyone throws the word AI around. You showed what it can actually deliver."
Ongoing Annual Retainer
"Two days of work. Reduced to less than one hour. I genuinely did not think that was possible."
Clear sequence. No ambiguity.
Focus: AI adoption at SHS fund level. How the team can use AI safely and effectively today. Initial orientation on regulatory landscape (BaFin, DORA). Practical next steps.
Guillaume discusses with Tobias and the Value Creation Team. Align on MTR as first pilot. Identify second candidate.
Confirm Fund-Level Advisory start date and MTR Pilot scope. KH Advisory delivers engagement letter for signature. Identify MTR's CRM and API access.
Discovery sessions at MTR. Visit Report Assistant deployed to pilot group of 10–20 reps. Fund-Level Advisory active -first monthly progress report delivered to SHS leadership.
EBITDA impact documented. Results presentation delivered. Board-ready summary for SHS. Decision: scale to more reps at MTR? Expand to next portfolio company? Portfolio Workshop?